Thus, our results indicate that MARK4 has potential as a regulator of mitochondrial injury associated with excessive back-fat in the pig placenta, and anti-MARK4 therapy targeted to inhibit oxidative stress and mitochondrial injury in cytotrophoblasts may serve as a novel therapeutic strategy for treatment of obesity-associated pregnant complications. The gene discussed is MARK4; the disease is obesity disorder.